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Abstract
Background Psychosocial and behavioral interventions trials targeting a broad range of
complex social and behavioral problems such as smoking, obesity and family caregiving have
proliferated in the past 30 years. At the same time the use of Data and Safety Monitoring
Boards (DSMBs) to monitor the progress and quality of intervention trials and the safety of
study participants has increased substantially. Most of the existing literature and guidelines
for safety monitoring and reporting of adverse events focuses on medical interventions.
Consequently, there is little guidance for investigators conducting social and behavior trials.
Purpose This paper summarizes how issues associated with safety monitoring and adverse
event reporting were handled in the Resources for Enhancing Alzheimer’s Caregiver Health
(REACH II) program, a multi-site randomized clinical trial, funded by the National Institutes on
Aging (NIA) and the National Institutes of Nursing Research (NINR), that tested the efficacy
of a multicomponent social/behavioral intervention for caregivers of persons with Alzheimer’s
disease.
Methods A task force was formed to define adverse events for the trial and protocols for
reporting and resolving events that occurred. The task force conducted a review of existing
polices and protocols for data and safety monitoring and adverse event reporting and
identified potential risks particular to the study population. An informal survey regarding data
and safety monitoring procedures with investigators on psychosocial intervention trials was
also conducted.
Results Two categories of events were defined for both caregivers and patients; adverse
events and safety alerts. A distinction was also made between events detected at baseline
assessment and those detected post-randomization. Standardized protocols were also
developed for the reporting and resolution of events that occurred and training of study
personnel. Results from the informal survey indicated wide variability in practices for data
safety and monitoring across psychosocial intervention trials. Conclusions Overall, the
REACH II experience demonstrates that existing guidelines regarding safety monitoring and
adverse event reporting pose unique challenges for social/behavioral intervention trials.
Challenges encountered in the REACH II program included defining and classifying adverse
events, defining “resolution” of adverse events and attributing causes for events that
occurred. These challenges are highlighted and recommendations for addressing them in
future studies are discussed.

Introduction
During the past 30 years, psychosocial and behavioral interventions designed to maintain
and improve health and quality-of-life have proliferated. Researchers have targeted a
broad range of complex social and behavioral problems such as smoking, obesity, medical
compliance and family caregiving. Recently, there has also been a growing demand for
evidence-based practice. Clinicians, social agencies and policy makers increasingly
require evidence about real-world effects of treatments when making decisions about
investing in intervention programs. In response, the randomized clinical trial (RCT) design,
recognized as the gold standard for evaluating medical interventions, is commonly used to
evaluate the effectiveness of behavioral intervention approaches.
To ensure that RCTs meet the highest scientific standards, many aspects of the design
and conduct of a clinical trial such as participant recruitment, treatment adherence,
intervention outcomes and participant safety must be carefully monitored. Toward this end,
the use of independent Data and Safety Monitoring Boards (DSMBs) to monitor the
progress and quality of a trial and participant safety has increased substantially [1,2]. In
fact, in an effort to improve the quality of clinical research and ensure the protection of
human subjects, the National Institutes of Health (NIH) has issued guidelines and
regulations to increase the use of data and safety monitoring within clinical trials. It is now
the policy of NIH that each Institute and Center should have a system for the appropriate
oversight and monitoring of the conduct of clinical trials to ensure the safety of the
participants and the validity and integrity of the data. A DSMB is required for all Phase III
multisite clinical trials involving potential risks to participants and may be required for
Phase I or II trials, and even smaller intervention studies if the study population is
vulnerable or other study characteristics support the need for an external board [3]. The
Federal Drug Administration (FDA) has also recently issued draft guidelines on the
formation and responsibilities of DSMBs for trials subject to FDA oversight. Theses
guidelines are fairly consistent with procedures followed for NIH-funded trials [4].
The primary role of a DSMB is to ensure the safety of trial participants, through review of
adverse events. A key secondary role is to preserve the quality and credibility of the trial in
order to provide reliable results to clinical and policy communities. Although there is
general agreement about the basic roles of DSMBs, how they are used and function varies
widely across trials and sponsoring agencies [5]. Many issues such as determination of
when DSMBs are needed, methods for conducting interim data analyses and
confidentiality of interim results remain controversial [6,7]. For example, questions often
arise about policies used to guide decisions about the safety and efficacy of trials.
Although a number of statistical approaches are available for assessing interim data these
statistical procedures in and of themselves are seldom sufficient for making
recommendations about trial termination and continuation. There are several cases
reported in the literature where strict adherence to the stopping rules established for a trial
would have led to less than optimal conclusions about the potential benefits or harm of a
treatment [6,8,9]. A related controversy is whether access to interim outcome data should
be restricted to DSMB members. The rationale for masking is preservation of trial integrity
and credibility and protection from bias. Arguments for unmasking are based on the
premise that excluding trial members from access to interim outcomes may result in
erroneous conclusions about treatment effects as DSMB members may not have access
to key information they need to interpret the results of the interim analysis. Clearly safety

monitoring can mean different things to different people, depending on their relationship to
a particular study.
Controversies also exist regarding the definition and reporting of adverse events.
Adverse events are generally defined as any unfavorable or unintended symptom, sign or
disease associated with a medical treatment or procedure that may or may not be related
to the treatment or procedure [10]. Investigators are typically required to report all AEs and
assess severity whether or not they are related to study treatments. In principle, the term
adverse event should be non-judgmental with regard to the relationship between treatment
and the event. AEs can be associated with the treatment, the disorder or behavior being
targeted, a concurrent disorder or treatment, or it may be entirely unrelated.
Existing guidelines for the definitions and reporting of AEs are somewhat broad and
vague. The current FDA guideline requires reporting of AEs that are “serious and
unexpected” whereas the NIH requires reporting of “unanticipated problems” posing risks
to study participants [11]. Clearly, there can be considerable variability in the interpretation
of terms such as “serious”, “unexpected” and “unanticipated”. Furthermore, existing
policies offer little guidance regarding required documentation and protocols for reporting.
Support for this view can be found in recent reviews of the AE literature which have
demonstrated fairly wide variance in the terms used to describe adverse events (eg,
adverse events versus side effects versus complications) as well as variations, even within
trials, in AE reporting, especially with respect to judgments of severity or relatedness
[12,13]. Consistency in AE documentation, characterization and evaluation is important
since lack of consistency can ultimately affect decisions about treatment adoption.
Judgments of causality must also take into account the complex dynamic interplay
between the inherent risks of the intervention and contextual factors such as comorbidities
related to a disease that can influence the type and frequency of AEs that occur within a
trial. Lack of understanding of these factors and their potential relationship to study
treatments can lead to biasing in data reporting and interpretation as well as poor
decisions about when to stop a trial.
Issues surrounding safety monitoring and AE reporting are even more complex for
social and behavioral intervention trials. Because most of the existing literature regarding
AEs is based on medical interventions, there exists little guidance for investigators
conducting social and behavior trials. To help fill this gap, this paper reports how issues
associated with safety monitoring and reporting of adverse events were handled in the
Resources for Enhancing Alzheimer’s Caregiver Health (REACH II) program. Data are
also reported from an informal survey conducted with investigators of other currently active
psychosocial intervention trials regarding data and safety monitoring procedures. The
overall goal of the paper is to identify the challenges of applying existing guidelines for
monitoring clinical trials for safety to social/behavioral intervention trials and to make
suggestions as to how they might be addressed in future studies.

Overview of the REACH II program
REACH II was a multisite randomized clinical trial, funded by the National Institutes on
Aging (NIA) and the National Institutes of Nursing Research (NINR) that tested the efficacy
of a multicomponent social/behavioral intervention for caregivers of persons with
Alzheimer’s disease. The randomized cohort consisted of 212 Hispanic/Latino, 219 white

Caucasian, and 211 black/African-American caregivers recruited from five sites in the US:
Birmingham, AL; Miami, FL; Memphis, TN; Palo Alto, CA; Philadelphia, PA. The study also
included a coordinating center at the University of Pittsburgh.
Eligibility
Eligibility criteria for caregivers included being Hispanic/Latino, white/Caucasian, or
black/African-American; being over the age of 21; living with or sharing cooking facilities
with the patient; providing care for a relative with Alzheimer’s Disease and Related
Disorders (ADRD) for a minimum of four hours per day for at least the past six months;
caring for a patient with memory or behavior problems, and feeling overwhelmed, or angry,
or having crying spells, or feeling cut off from family or friends because of caregiving
demands. Caregivers were excluded if they were involved in another caregiver
intervention study, participated in the earlier REACH I trial, or had an illness that would
prevent them from participating for at least six months. Other requirements were logistical
and included having a telephone, planning to remain in the geographic area for at least six
months, and competency in either English or Spanish.
In order to be eligible for the study, caregivers had to confirm that their relative had a
diagnosis of Alzheimer’s disease or related dementia. Patients who scored above 23 on
the Mini-Mental State Exam [14] were required to have a physician’s diagnosis of
Alzheimer’s disease or a related disorder.
Protocol
Participants were screened for eligibility, given a baseline assessment, and subsequently
randomized to treatment or control condition within each of the three ethnic groups.
Caregivers were assessed a second time six months later after the intervention was
completed. The intervention was designed to improve the quality of life of caregivers in
multiple domains. Therefore, the primary outcome was a multivariate quality of life
indicator that assessed caregiver burden, depressive symptoms, self-care, social support,
and patient problem behaviors. In addition, caregiver clinical depression and patient
institutional placement were assessed.
Study design
The design of the intervention was guided by consideration of the existing literature and
findings from the multisite REACH I [15,16]. The evidence from both sources indicated that
caregiving presents multiple challenges and that there is no single, consistently effective
method for achieving clinical significance effects among caregivers. As a result, the
intervention was based on a risk appraisal approach and five areas linked to caregiver
stress health processes: burden, depression, self-care, social support and care recipient
problem behaviors [17] were matched to five corresponding intervention components.
Because there is considerable variability in the needs of caregiver/care recipients, a
structured risk appraisal was administered at baseline and dosing was adjusted to level of
risk present within each area. For example, a person who had minimal problems with
depression would only receive a small dose of the intervention component designed to
improve emotional wellbeing. To deliver the intervention in a cost effective manner the
intervention was administered using a combination of in-home visits augmented by
telephone/computer technology in 12 sessions over six months. In addition, five telephone

administered cross-site support group sessions were available to intervention arm
participants. Caregivers were also provided with a Caregiver Notebook that contained
basic educational materials as well as other instructional materials provided by the
interventionist during the home sessions.
In contrast, caregivers in the control arm received a packet of basic educational
materials and two brief (<15 minute) telephone “check-in calls” at three and five months
post randomization. They were also invited to participate in a workshop on dementia and
caregiving following the six-month assessment. All materials were available in English and
Spanish.

Overview of safety monitoring in REACH II
Because REACH II was a multisite intervention trial and involved a vulnerable population
(caregivers and dementia patients) an independent DSMB was required by the sponsoring
agencies. The members of the DSMB were identified by the sponsoring agencies, with
recommendations from the Trial Steering Committee, prior to the start of the study. The
five members included experts in intervention research, caregiving, biostatistics, and
ethics. The primary responsibilities of the DSMB included monitoring of participant
recruitment and safety, protocol compliance, and data quality. The DSMB met twice
yearly; once in person and once by conference call. They received data reports a month
prior to each meeting that contained information about participant recruitment, retention,
participant characteristics and adverse events. In addition to the DSMB members meeting
attendees included the program officers from the NIA and the NINR, the study statistician,
the Principal Investigator of the Coordinating Center and the Chair of the REACH II
Steering Committee.
At the initial meeting, the DSMB reviewed the study protocol (eg, informed consent
forms, intervention protocols, data collection instruments), and agreed upon data reporting
requirements (frequency, type of data and reporting format). They also reviewed the
definitions of adverse events and protocols for resolution of those events adopted for the
trial (Table 1). At subsequent meetings the DSMB reviewed the progress of the study (eg,
recruitment by race/ethnicity at each site, protocol deviations, intervention adherence,
adverse events, site visit summaries, data quality, attrition, effectiveness of randomization
procedures) and made recommendations concerning its continuation. The decisions of the
DSMB were considered advisory to the NIH. Formal stopping rules were not specified for
the trial.
The DSMB worked with the Coordinating Center and the program officers to choose a
monitoring approach that best suited the study. An interim data analysis, performed by the
trial statistician, was also conducted. To avoid potential bias, all site investigators and the
PI of the Coordinating Center were masked to the results of the interim analyses. The
Coordinating Center generated minutes for each of the DSMB meetings which were then
submitted to the NIA, NINR and the sites who then distributed the minutes to the local
Institutional Review Boards (IRB).

Challenges encountered in the REACH II program
Defining and classifying adverse events (AEs)
One of the initial challenges faced by the REACH II investigators was defining and
classifying AEs for the trial. To facilitate this process a task force with representatives from
each of the five sites, the coordinating center, and the sponsoring agencies was formed.
Given that this was a multisite trial, it was important to ensure that the definition of AEs
was standardized across the five intervention sites. In addition, as the focus of the trial
was the dyad, AEs needed to be defined for both the caregiver and the care recipient.
Also, the intervention was based on a risk appraisal approach and a baseline
assessment, which included measures of depression, quality of care, care recipient
problem behaviors was administered prior to randomization. Thus, AEs and potential risks
to the participants could be detected prior to the start of the intervention. For example, the
risk appraisal questionnaire asked caregivers if the care recipient had threatened to harm
him or herself or others, had access to a gun or was still driving. Although, events detected
at baseline could not be attributable to the intervention, because of ethical and IRB
requirements they needed to be reported and addressed. Consideration also needed to be
given to the characteristics of the participant population and contextual factors surrounding
the caregiving situation. For example, dementia patients are likely to be elderly and have
medical or behavioral comorbidities such as wandering or aggression. Likewise, it is not
uncommon for caregivers to suffer from depressive symptoms. While these types of
events do not fall under the standard definition of serious AEs they still pose a potential
risk to the individual. Finally, as noted, the population was ethnically diverse and events
such as institutionalization of the patient tend to be more common among some caregiver
populations (eg, non-Hispanic whites) as opposed to others (eg, Hispanics/Latinos) [18].
Based on these considerations, we distinguished among two categories of events:
adverse events and safety alerts. The definition of “adverse event” was consistent with
traditional definitions of AEs and included events such as death, hospitalization and
emergency room visits. “Safety alerts” were events that were relevant to the study
population and posed safety risks to study participants. Examples of safety alerts included
caregivers having symptoms of depression or the care recipient driving (Table 1). A
distinction was also made between events that were detected at baseline (baseline adverse
events and baseline safety alerts) versus those that occurred following randomization and
the six-month follow-up assessment (adverse events and safety alerts).
Defining “resolution”
A second task involved defining what constituted “resolution” of a safety alert or an
adverse event. This task was challenging as events such as institutionalization are
common among dementia patients and often permanent. For example, a question arose
regarding resolution of patient institutionalization. Should resolution be defined as the
return of the patient to the home setting or simply knowledge that placement occurred and
the reason for the placement decision? Obviously, placement of patients who were
permanently placed would never be “resolved” if the definition of resolution of this event
was the patient returning to home. The final definitions of resolution for AEs and safety
alerts are presented in Table 1.

The definitions of adverse events and safety alerts and protocols for event resolution
were submitted to the DSMB for review and approval. An important aspect of this process
was educating the DSMB about the nature of the intervention and the characteristics of the
target population. Although all of the members of the DSMB had experience with clinical
trials and expertise in intervention research some of the members had limited expertise
with caregiving and dementia patients. Following approval by the DSMB, study personnel
(assessors and interventionists) at the five intervention sites and the Coordinating Center
were trained in protocols for identification, reporting and resolution of AEs and safety
alerts. These protocols were also included in the manual of operations.
As shown in Table 2, the most common events among caregivers were evidence of high
levels of depressive symptoms. Among care recipients, the most common events were
hospitalization, comments related to death, institutionalization and death. Also, as
indicated there was some variation in frequency of event according to ethnicity of the
dyad. Institutionalization, access to a gun and continued driving was more common among
the white/Caucasian care recipients as compared to the Hispanic/Latino and black
American care recipients.
Reporting requirements and attribution
Developing a standardized reporting system was also complicated given differences in
requirements among the site IRBs. Some sites were required to report all events to the
local IRB irrespective of event severity whereas other sites were only required to report
AEs and not safety alerts. The DSMB required reporting of all events.
To help ensure consistency in reporting across the sites, adverse events and safety
alerts were tracked using standardized forms that recorded the date of the event, type of
event, attribution of the event (eg, was it intervention related), whether the event was
resolved or controlled and the resolution date. These forms were completed by the site PI
or designee (eg, clinical supervisor, project coordinator) and faxed to the Coordinating
Center within 24 hours of learning of the event. Sites were also required to complete an
Adverse Event Resolution Note which further detailed the specifics of the how the event
was addressed.
The issue of attribution proved to be somewhat of a challenge for the REACH II
program. Events such as hospitalization are common among dementia patients given the
nature of the illness and the fact that dementia patients tend to be elderly and have other
comorbid conditions. In fact, in the REACH II trial hospitalizations were the most common
AE among the care recipients (Table 2). Though unlikely to be related to the intervention,
the relatively high frequency of hospitalizations generated concern among the members of
the DSMB, particularly since more were reported for care recipients in the intervention
condition than in the control arm (Table 3). Because of this concern, the DSMB required
further analyses of these events. It was determined that the higher frequency of
hospitalizations among care recipients in the intervention condition was likely due to
greater contact between the interventionists and caregiver who received the intervention
and not related to the intervention. Similar issues arose for care recipient emergency room
visits. The problems associated with determining attribution experienced in the REACH II
program highlight the difficulties of applying existing definitions of AEs, developed for
medical intervention, to social behavioral intervention trials. In addition, this issue
underscores the importance of ensuring that members of the DSMB understand the nature

of the intervention, the disease or behavioral problem of interest and the characteristics of
the target population. A lack of understanding of these factors among DSMB members can
potentially lead to erroneous decisions about the safety and impact of the intervention.

Results of the informal survey
As noted, the authors were interested in ascertaining to what extent the adverse event
issues encountered in the REACH II project were shared by other researchers conducting
psychosocial clinical trials. To address this question, we conducted an informal survey
with Principal Investigators of other trials via questionnaire. The questionnaire consisted
of 22 items, including yes/no, checklist, and open ended questions regarding
challenges/difficulties encountered related to data safety monitoring and the reporting of
adverse events.
Sample
Trials (N = 84) were identified from the NIH.GOV and Clinical Trials.Gov websites. The
search was limited to behavioral and social intervention trials or trials that combined
behavioral and medical interventions and were currently active. The survey instrument
was mailed to the Principal Investigator of the identified trials. The response rate was
49% (N = 41).
The interventions being evaluated in the studies that responded included cognitive and
psychosocial interventions (47%), education (18%), skills training (14%), exercise (10%),
medically-related (8%) and mind/body interventions (2%). The study populations included
patients with chronic diseases (39%), mental-health problems (29%), family caregivers
(15%), and older persons with physical frailty (7%) or cognitive impairment (2%). Eighty
percent (N = 33) of the trials included a control condition such as standard care (42%),
placebo, information only or no treatment control (38%). The remaining studies did not
include a control group and were not randomized trials. Seventy-one per cent of the trials
(N = 29) were multisite.

Data safety monitoring and AEs
Results of the survey indicated that there was considerable variability among the trials in
protocols for data and safety monitoring. Fifty-four per cent of the trials had a formal
DSMB; 37% had a monitoring plan but no external Board, and 10% reported using
neither. As expected, formal DSMBs were more common among multisite trials (83%) as
compared to single site trials (41%). Only 31% of the studies with DSMBs had formal
stopping rules for trial termination. The type of data reported to the DSMB varied. Most
trials reported data related to the occurrence of serious (83%) or other types of AEs
(71%), participant recruitment (71%) and retention (76%). However, reporting of data
related to participant baseline characteristics (51%), data quality (46%) and data
timeliness was less common (37%). Several trials did not report AEs or serious AEs.
Only 78% of the trials had established protocols for defining adverse events; 60% had
established protocols for reporting the attribution/causality of serious adverse events and
45% had such protocols for other-than-serious events. AEs were identified through a

variety of sources including participant self-report (77%), interventionists interaction with
the participant (77%) or standardized questionnaires at schedules assessments (54%). In
most studies attribution was determined by the Principal Investigator (85%) or the IRB
(67%). Similarly resolution was typically determined by the Principal Investigator (64%) or
the IRB (64%).
Key challenges
Investigators were also asked to describe any challenges or problems that arose during
the trial related to safety monitoring or reporting of adverse events. Commonly reported
problems included definition of what constituted an adverse event (especially for those
trials that included a vulnerable population), determination of attribution and lack of
consistency in reporting of AES by study staff. Overall, the list of problems was similar to
the challenges faced by the REACH II investigators.

Discussion
In an effort to improve the quality of clinical research and ensure the safety of research
participants, safety monitoring is becoming an integral component of clinical research
projects. Potential benefits associated with safety monitoring include early identification of
treatments that pose risk to individuals or which are likely to be ineffective, information on
the extent to which recruited participants reflect the profile anticipated and overall
improvements in data quality. Summary data on adverse events can also provide useful
insights into the needs of study populations and aid in the design of future intervention
approaches. Currently however, guidelines for data safety monitoring are somewhat
broad and vary across sponsoring agencies, including agencies within the federal
government. As a result there is wide variability in policies and protocols for conducting
data and safety monitoring and much debate surrounding issues related to the use of
DSMBs, stopping rules, and definition and reporting of adverse events. Questions
regarding safety monitoring are especially complex for social/behavioral intervention
trials.
This paper describes the protocols adopted for safety monitoring within the REACH II
project, a multisite randomized clinical trial that evaluated the efficacy of a
multicomponent psychosocial intervention for caregivers of dementia patients. Unique
characteristics of the REACH II program included a risk-appraisal based intervention
approach, a focus on the dyad, and inclusion of an ethnically diverse and vulnerable
study population. Challenges that were encountered in developing a plan for safety
monitoring in the REACH II program included defining and classifying adverse events,
defining “resolution” of adverse events and attributing causes for events that occurred.
Results of an informal survey suggest that these problems are not unique and common in
other behavioral trials.
On the basis of the REACH II experience, the following is a summary of
recommendations for implementing the existing guidelines for safety monitoring in social
behavioral trials. Our intent is to provide suggestions rather than a prescription as it is
recognized that models for data and safety monitoring vary according to the need and
characteristics of a particular trial.

Data and safety monitoring boards (DSMBs)
One issue that needs to be addressed is the need for, composition and role of the data
safety and monitoring board (DSMB). Prior to the start of the trial the role of the DSMB
also needs to be clearly defined as do protocols for data reporting and interim analyses.
In some cases having the DSMB members serve only in a scientific advisory capacity as
opposed to a formal board who makes decisions about trial termination may be sufficient.
In other cases, a formal DSMB may not be needed and a safety monitoring plan may be
adequate. The degree of monitoring should be based on the study’s risk profile. Factors
to be considered in the risk assessment include the characteristics of the population being
studied; risks associated with the intervention from prior studies and potential risks to the
study population in the absence of the intervention [19]. For example, for vulnerable
populations such as dementia patients a higher risk must be assumed.
If a formal DSMB is required, protocols for the structure, function and responsibilities of
the DSMB as well as the format and content of DSMB reports, statistical procedures and
monitoring guidelines should be clearly established before the start of the trial. Ellenberg
and colleagues [7] and the DAta MOnitoring Committees: Lessons, Ethics, Statistics
(DAMOCLES) study group [20] maintain that intervention trials would benefit from the
development of a charter outlining the protocols and responsibilities for data and safety
monitoring. Both groups provide examples of such a charter that encompass guidelines
for DSMB membership, responsibilities of the DSMB, protocols for the organization of
DSMB meetings, data reporting, interim data analyses and decision making and reporting
hierarchies. However, these charters while useful as guidelines are primarily oriented at
medical intervention trials and may need to be adapted for psychosocial interventions.
Furthermore, they do not address the issue of defining adverse events and determining
what constitutes “satisfactory” resolution of events that occur. We recommend that these
proposed charters be considered a reference and perhaps checklist for the issues that
need to be addressed if a formal DSMB is required for a trial.
If a formal DSMB is required, the committee must include individuals with expertise in
the clinical area being studied and the target population. Expertise in both is needed to
ensure appropriate interpretation of adverse events. For example, in the case of REACH
II having expertise in both care-giving and Alzheimer’s Disease was important. Having
individuals with some knowledge and experience with clinical trials and data safety
monitoring is also valuable. In any case, it is essential that all members of a DSMB have
a thorough understanding of the intervention protocol, the problem area being addressed
and the characteristics of the study population.
However, the size of the committee is also an important consideration as the number of
members is likely to have an impact on the quality of the decision process.
Identifying and defining adverse events
Careful consideration also needs to be given defining what constitutes an adverse event
for a trial. Defining adverse events, according to criteria developed for medical trials, may
not be appropriate for some types of interventions. As demonstrated in REACH II events
such as hospitalization and placement are common among patients with dementia and
unlikely to be related to behavioral interventions. Reporting these types of events and
investigating their causes may place undue burden on study personnel, DSBM members

and local IRBs. A more effective strategy would be to have DSMB members and
investigators reach consensus about those adverse events important for assuring the
safety and well-being of specific study population enrolled in the study. These judgments
should be based on the types of individuals and problems being studied, the nature of the
interventions being tested, as well as the findings from related prior research. Since
ascertaining the causes of adverse events can be labor intensive and costly, the focus
should be on adverse events that reasonably might be linked to the intervention.
Protocols for monitoring and reporting adverse events
Protocols also need to be developed for standardized tracking and reporting of adverse
events. These protocols need to include delineation of the type of data that needs to be
reported (eg, group versus site level data), and the timing and frequency of data reports.
This is especially important for multisite trials to ensure consistency in data reporting.
Where possible, there should also be consistency in reporting requirements between local
IRBs and the sponsoring agencies. This would help minimize duplication of effort and
costs associated with data reporting. For example, in the case of REACH II, differences in
event report forms required by local IRBs and those developed for the caused a
duplication of effort for study personnel. Equally important is insuring that study personal
are trained in protocols for identifying and reporting adverse events. Criteria also need to
be established for assigning event attribution.
Interim data analysis
Finally, procedures for the interim data analyses need to be clearly established prior to
initiating the trial. Important issues that need to be considered include the outcome
measures that will be included in the analyses, who will conduct the analyses, who will
be included in the discussion of the analysis, and the extent to which the investigators
are masked with respect to study outcomes. With respect to the issue of masking, we
recommend that, at minimum, the study statistician be included in the discussion of the
results of the interim analyses to ensure that the findings are interpreted appropriately
by DSMB members.
Overall, there are a number of issues with data safety monitoring that need to be
addressed within clinical trials. These issues are likely to become more salient as the
demand for evidence-based treatment and translational research continues to grow.
Practices for data and safety monitoring need to achieve an appropriate balance
between the protection of research participants and maximizing the quality and scientific
validity of research trials. It is hoped that the lessons learned from the REACH II trial will
help other investigators establish protocols for data and safety monitoring in social/
behavioral intervention trials.
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Table 1 Definitions of adverse events and safety alerts and protocols for resolution used in the REACH II program
Baseline adverse
events

Resolution

Caregiver death

a

Adverse events

Resolution*

Not applicableb

Caregiver death

The PI or designee (eg, clinical
supervisor, project coordinator)
obtained information regarding
the circumstances of the event

Caregiver
hospitalization

Not applicable

Caregiver
hospitalization

The PI or designee (eg, clinical
supervisor, project coordinator)
obtained information regarding
the reason for the hospitalization
and the status of the caregiver

Caregiver
institutionalization

Not applicable

Caregiver
institutionalizati
on

The PI or designee (eg, clinical
supervisor, project coordinator)
obtained information regarding
the reason for the
institutionalization and the status
of the caregiver

Caregiver emergency
visit

Not applicable

Caregiver
emergency
room visit

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the reason for the
emergency room visit and how
the problem was handled (eg,
received treatment, is currently
under treatment and/or is being
monitored by health care
provider)

Care recipient death

Not applicable

Care recipient
death

The PI or designee (eg, clinical
supervisor, project coordinator)
obtained information regarding
the circumstances of the event

Care recipient
hospitalization

Not applicable

Care recipient
hospitalization

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the reason for the
hospitalization and the status of
the care recipient

Care recipient
institutionalization

Not applicable

Care recipient
institutionalizati
on

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the care giver to
determine the reason and
planned duration of the
institutionalization

Care recipient
emergency room
visit

Not applicable

Care recipient
emergency
room visit

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the reason for the visit
and how the problem is being
handled (eg, received treatment,
is currently under treatment
and/or monitoring by health care
provider)

continued

Baseline safety
alerts

Resolution

Safety alerts

Resolution

Caregiver severe
c
medical problem

The PI or designee (eg, clinical
supervisor, project coordinator)
determined the nature of the
problem and how the problem
was handled (eg, received
treatment, is currently under
treatment and/or monitoring by
health care provider) and
referred the CG to their primary
other care physician (or other
health care professional)

Caregiver severe
medical
problem

The PI or designee (eg, clinical
supervisor, project coordinator)
determined the nature of the
problem and how the problem
was handled (eg, received
treatment, is currently under
treatment and/or monitoring by
health care provider) and referred
the CG to their primary care
physician (or health care
professional)

Caregiver CESD
score ≥ 15

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
discuss the seriousness of the
situation and referred them to
their primary care physician (or
other health care professional)
to discuss their symptoms

Caregiver CESD
score ≥ 15

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to discuss
the seriousness of the situation
and referred them to their primary
care physician (or other health
care professional) to discuss their
symptoms

Caregiver abuse

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
situation and to devise a plan of
action. The caregiver was
advised to contact their primary
care physician. If the caregiver
refused or was not able to
control the situation Adult
Protective Services may be
contact by the site

Caregiver abuse

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
situation and to devise a plan of
action. The caregiver was
advised to contact their primary
care physician. If the caregiver
refused or was not able to control
the situation Adult Protective
Services may be contact by the
site

Care recipient severe
medical problem

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
problem and how the problem
was handled (eg, received
treatment, is currently under
treatment and/or monitoring by
health care provider) and
referred the CG to their primary
care physician (or other health
care professional)

Care recipient
severe medical
problem

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
problem and how the problem
was handled (eg, received
treatment, is currently under
treatment and/or monitoring by
health care provider) and referred
the CG to their primary care
physician (or other health care
professional)

Care recipient
threatens to hurt
him/herself three
or more times in
the past week

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
discuss the statements made
by the care recipient and
devise a plan of action with the
CG. The CG was advised to
monitor the patient and if the
situation persists to contact
their primary care physician.

Care recipient
threatens to
hurt him/herself
three or more
times in the
past week

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to discuss
the statements made by the care
recipient and devise a plan of
action with the CG. The CG was
advised to monitor the patient and
if the situation persists to contact
their primary care physician.

continued

Baseline safety
alerts

Resolution

Safety alerts

Resolution

Care recipient has
access to a gun

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
discuss the safety implications
and devise a plan of action to
block the care recipient’s
access to the gun. If the CG
refused or was unable to block
the CR’s access Adult
Protective Services may have
been contacted. If it appears
that an assessor or
interventionist was in danger
the CGs/CR’s participation in
the study was terminated

Care recipient has
access to a
gun

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to discuss
the safety implications and devise
a plan of action to block the care
recipient’s access to the gun. If
the CG refused or was unable to
block the CR’s access Adult
Protective Services may have
been contacted. If it appears that
an assessor or interventionist was
in danger the CGs/CR’s
participation in the study was
terminated (unless it was the sixmonth followup)

Care recipient driving

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
discuss the safety implications
of the CR driving and devise a
plan of action to stop the care
recipient from driving. CGs
who were randomized to the
control condition were sent the
material on driving and
dementia. CGs who were
randomized to the intervention
condition were encouraged to
read the materials in the
Caregiver Notebook related to
driving

Care recipient
driving

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to discuss
the safety implications of the CR
driving and devise a plan of action
to stop the care recipient from
driving. CGs were encouraged to
read the materials that they have
received related to driving

Care recipient abuse

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
situation and devise a plan of
action. If the caregiver refused
or was not able to control the
situation Adult Protective
Services may have been
contacted by the site

Care recipient
abuse

The PI or designee (eg, clinical
supervisor, project coordinator)
contacted the caregiver to
determine the nature of the
situation and devise a plan of
action. If the caregiver refused or
was not able to control the
situation Adult Protective Services
may have been contacted by the
site

a

Resolution means that the problem has been addressed with the caregiver; where appropriate (eg, CR driving; access to a
gun) and a plan of action and recommendations are discussed and no further action by the research team is required.
b
Resolution of baseline adverse events was considered as not applicable due to the fact that the intervention had not yet
begun, therefore there was no concern about event being caused by intervention and the occurrence of this type of event at
baseline would have precluded the dyad from being randomized in the trial.
c
Severe medical problem is defined as an illness (medical or emotional) or injury that impairs a person’s daily functioning or
causes high levels of subjective distress. Examples might include: urinary tract infection, chronic cough, flu, broken limb
(resulting from a fall).

Table 2 Adverse events and safety alerts in REACH II by ethnicity
No. events at baseline
Hispanic

White

Black

Total

96/212

132/219

66/211

294/642

CG CES-D score 15 or more

55

52

38

145

CG hospitalization

0

0

0

0

CG emergency room visit

0

0

0

0

No. Safety alerts or AEs/No. participants
CG events

CG several medical problem

0

0

0

0

CG institutionalization

0

0

0

0

CG death

0

0

0

0

CG other event

1

0

0

1

CR events
CR hospitalization

2

1

1

4

CR institutionalization

0

0

0

0

CR emergency room visit

0

1

1

2

CR death

0

0

0

0

CR severe medical problem

0

0

0

0

CR commented of death 3 X or more

23

23

10

56

CR threatened to hurt 3 X or more

4

2

0

6

CR access to a gun

3

26

10

39

CR driving

5

27

5

37

CR other event

3

0

1

4

Hispanic

White

Black

Total

138/212

203/219

158/211

499/642

CG CES-D score 15 or more

40

29

24

93

CG hospitalization

5

14

15

34

CG emergency room visit

6

8

7

21

CG several medical problem

8

1

5

14

CG institutionalization

0

1

0

0

CG death

0

0

1

0

CG other event

5

2

5

12

No. events post-randomization
No. safety alerts or AEs/No. participants
CG events

CR events
CR hospitalization

25

46

40

111

CR institutionalization

7

29

9

45

CR emergency room visit

7

15

5

27

CR death

10

16

20

46

CR severe medical problem

6

2

5

13

CR commented of death 3 X or more

13

11

8

32

CR threatened to hurt 3 X or more

0

2

2

4

CR access to a gun

0

12

6

18

CR driving

3

15

4

22

CR other event

3

0

2

5

*CG/CR abuse events did not occur.

Table 3 Post-randomization adverse events and safety alerts by intervention condition

No. events
Control

Intervention

Total

203/319

296/323

499/642

CG CES-D score 15 or moreb
CG hospitalization
CG emergency room visit

59
12
3

34
22
18

93
34
21

CG severe medical problem
CG institutionalization

1
1

13
0

14
1

1
6

0
6

1
12

29
22

82
23

111
45

CR emergency room visit
CR death
CR severe medical problem
CR commented of death 3 X or more

3
22
2
19

24
24
11
13

27
46
13
32

CR threatened to hurt 3 X or more
CR access to a gun
CR driving

3
8
11

1
10
11

4
18
22

CR other event

1

4

5

No. safety alerts or
AEs/No. participants
CG eventsa

CG death
CG other event
CR eventsa
CR hospitalization
CR institutionalization

a

CG/CR abuse events did not occur.
Based on 10 item version of CES-D (possible range 0–30).

b

